Richard S. Finn

BackgroundPembro received accelerated approval for second-line therapy in pts with advanced HCC, based on the phase 2, KEYNOTE-224 trial. KEYNOTE-240 was a randomized, phase 3 study of P...

Marcelo Garrido ;

Stephen Lam Chan , MD;

Jennifer J. Knox ;

Bruno Daniele ;

Scot Ebbinghaus ;

Erluo Chen ;

Abby B. Siegel ;

Julien Edeline ;

Baek-Yeol Ryoo ;

Ann-Lii Cheng , MD, PhD;

Philippe Merle ;

Masatoshi Kudo , MD, PhD;

Mohamed Bouattour ;

Richard S. Finn ;

Ho-Yeong Lim ;

Andrew Zhu ;

Valeriy Vladimirovich Breder , MD, PhD;

Yee Chao ;

Sadahisa Ogasawara ;

Thomas Yau ;

07/01/2019

CIO 2022-33 Atezolizumab + Bevacizumab vs Sorafenib in HCC Patients With Prior Locoregional Therapy: IMbrave150 Exploratory Data

BEST POSTER WINNER Late-breaking abstract / Here, we report post hoc exploratory results of atezo + bev vs sorafenib (sor) in pts who had prior LRT using updated IMbrave150 data with 12 m...

Michel P. Ducreux , MD, PhD;

Sairy Hernandez ;

Amit G. Singal ;

Wendy Verret ;

Allan Nicholas , MD, FACC;

Riad Salem , MD, MBA;

Richard S. Finn ;

Peter R. Galle , MD, PhD;

Andrew Zhu ;

Philippe Merle ;

10/17/2022